p38α inhibitor 1

CAS No. 1034189-82-6

p38α inhibitor 1( P38alpha inhibitor 1 | ARRY-797 | P38a inhibitor 1 )

Catalog No. M26356 CAS No. 1034189-82-6

p38α inhibitor 1 is an inhibitor of p38α .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 86 Get Quote
5MG 122 Get Quote
10MG 203 Get Quote
25MG 357 Get Quote
50MG 530 Get Quote
100MG 759 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    p38α inhibitor 1
  • Note
    Research use only, not for human use.
  • Brief Description
    p38α inhibitor 1 is an inhibitor of p38α .
  • Description
    p38α inhibitor 1 is an inhibitor of p38α .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    P38alpha inhibitor 1 | ARRY-797 | P38a inhibitor 1
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1034189-82-6
  • Formula Weight
    416.473
  • Molecular Formula
    C22H26F2N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 125 mg/mL (300.15 mM)
  • SMILES
    CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(cc12)C(=O)NCCN(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Moncrieff M, Fadhil M, Garioch J. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience. Br J Dermatol. 2015 Nov 24.
molnova catalog
related products
  • MW181 dihydrochlorid...

    MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM.

  • EAI045

    EAI045, an allosteric inhibitor, targets towards drug-resistant EGFR mutants but avoids the wild-type receptor.

  • AKP-001

    AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.